77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two years Initiation of OCREVUS as first-line
Investegate announcements from F. Hoffmann-La Roche Ltd, Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
The PRAME (EPR20330) Antibody evaluates PRAME protein expression from patients with suspected melanoma. Understanding if the PRAME protein is expressed helps enable more informed clinical decisions and
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. These patients with HER2 low status may now be eligible for a targeted treatment, which could significantly
Phase III data that showed people with nAMD and DME treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with aflibercept In addition